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ORIGINAL RESEARCH

Use of Urine Antigen Testing for Blastomyces in an
Integrated Health System
Dennis J. Baumgardner, MD
Aurora UW Medical Group, Aurora Health Care, Milwaukee WI; Department of Family Medicine and Community Health,
University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health,
Milwaukee, WI

Purpose	Blastomycosis, an endemic fungal infection, mimics many other diseases. We explored the use of
Blastomyces urine antigen (BuAg), reportedly the most sensitive noninvasive test, in clinical practice
and compared it to other noninvasive tests.
Methods

 total of 836 BuAg tests performed on unique patients (first test only) at one large integrated health
A
system from June 2013 to May 2016 were retrospectively reviewed to examine test characteristics and
demographic features. Of these, 100 cases from 2015, a year containing a large local blastomycosis
outbreak, were randomly selected for detailed analysis.

Results 	Demographics for the BuAg-tested population: mean age 54.9 years, 55.0% male, 78.9% white, 213
zip codes represented. Test results were positive in 49 of 836 (5.9%, across 43 zip codes); 16 of the 49
(32.7%) stemmed from the 2015 outbreak. BuAg-positive patients were younger than those who tested
negative, even with outbreak subjects removed (48.1 vs 56.7 years, P=0.008); and Asians and males were
overrepresented. Sensitivity/specificity/positive predictive value of BuAg test was 87.9%/97.9%/76.3%,
respectively, based on 33 culture-positive cases. Only 2 of 20 culture-positive cases were found positive
by Blastomyces antibody (Ab) immunodiffusion (ID) test and 0 of the other 18 by Ab complement fixation
(CF). Of those with positive BuAg who were co-tested, 16.1% were positive by Ab ID and 3.9% by Ab
CF. Histoplasma urine antigen was co-performed with BuAg in 578 patients (69.1%) and positive in 25
(4.3%); 16 of these 25 (64.0%) also were BuAg-positive (ie, known cross-reactivity). Of the 100 patients
examined for index illness details, 7 (6 BuAg-positive) were ultimately diagnosed with blastomycosis, 7
other fungal disease, 26 noninfectious lung disease, 22 pneumonia, 5 skin lesions, 6 malignancies, 3
mycobacteria, 11 other, and 1 unknown. Of 100, 12 were tested by BuAg based on symptoms.
Conclusions	
Blastomyces urine antigen is commonly used for work-up of broad differential diagnoses or known
exposures. Not adding Ab ID/CF diagnostic tests ($80 each) to the BuAg test saves money without
losing sensitivity. (J Patient Cent Res Rev. 2018;5:176-182.)
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B

lastomycosis is a potentially serious systemic
and cutaneous fungal infection endemic
to eastern North America.1-3 Disease is
acquired from the environment by inhalation of
spores of the etiologic fungi Blastomyces dermatitidis
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or Blastomyces gilchristii.2,4 Incidence rates are
particularly high in Wisconsin compared to the rest
of the nation.2,5 Pulmonary disease, the most common
clinical manifestation, has a broad differential
diagnosis,1,6,7 and proper diagnosis is important to avoid
increased morbidity and mortality. Dissemination
beyond the lung may occur to most any organ or
tissue, particularly skin, bone, genitourinary system
and central nervous system.1,2,6 Thus, the differential
diagnoses of various presentations of blastomycosis
may be quite broad.1,6
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Fungal culture is reportedly 86% sensitive in
pulmonary cases and may take up to 5 weeks for the
organism to grow.8 Fungal smears for rapid diagnosis
vary from 24% to 55% sensitivity depending on the site
sampled.3 Blastomycosis diagnosis by histopathology,
compared with culture, was 85%–89% sensitive in two
studies.9,10 Modern serologic tests approach 80%–90%
sensitivity; however, antibody testing by complement
fixation (CF) or immunodiffusion (ID) is insensitive.1,2
Urine antigen testing for Blastomyces (BuAg) has
been described for the past 14 years,11 though it has
only been commercially available and more frequently
utilized in the past few years. It uses readily available,
noninvasive urine samples, and turnaround time is
frequently within 48 hours, much sooner than fungal
culture. Reported sensitivities range from 76% to
93%,11-15 with specificities of 77%–79%.11,15 Specificity
improved to 99% by using control subjects who
were healthy or had nonfungal infections, and by use
of urine antigen detection by quantitative enzyme
immunoassay.12 There is, however, significant crossreaction in patients with histoplasmosis.11,12
Increased use of BuAg may be leading to more
blastomycosis diagnoses in community settings.13
However, there have been few studies that have
examined the epidemiologic and clinical features
of patients on whom this test is ordered and test
characteristics in a general patient population.13,14 This
study explored the demographic and clinical features
of patients on whom BuAg is performed, as well as
test characteristics, in an eastern Wisconsin integrated
health system. Understanding of these features may
guide clinicians regarding the usefulness of this test in
patients who may have blastomycosis and its ability to
supplant older serological tests.

METHODS

Setting and Subject Selection
Subject identifiers for this retrospective electronic
medical records (EMR) review were obtained from
the affiliated laboratory of a large, integrated health
system that included, at the time of the study, 15
hospitals and 159 outpatient clinics throughout eastern
Wisconsin and extreme northeastern Illinois. This
area contains the majority of Wisconsin’s urban and
suburban population. Our system houses medical
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records of more than 1.2 million unique patients. The
geodemographic features of blastomycosis cases in
our health system have been previously described.16
Approvals for the present study were obtained from
the local institutional review board.
Subjects included all inpatients and outpatients,
regardless of age, who had BuAg processed through
our laboratory during the time period June 2013 to
May 2016. All BuAg tests within the study period
were performed at our reference laboratory, which
uses quantitative sandwich enzyme immunoassay
technology to detect a galactomannan found in the
cell wall.12 The first BuAg performed during this
time period on each unique patient was examined as
the “index test.” Subsequent BuAg tests also were
recorded. Additional blastomycosis case finding
(including diagnosis by culture, histopathology, and/
or cytology/smear) over this same time period was
obtained from a search of inclusive ICD-9/10 codes by
our institution’s research analytics department.
These patient lists were used to perform chart review on
all subjects for demographic features and to calculate
test characteristics of BuAg, including comparison
to the other common noninvasive diagnostic tests
for Blastomyces, CF and ID. For these comparisons,
other tests for Blastomyces were included if they
were obtained during work-up of the same inpatient
or outpatient illness episode as the BuAg test. For
fungal culture or histo/cytopathology, these tests
were generally concurrent but always within 33 days
(sometimes awaiting bronchoscopic examination). For
CF and ID tests, virtually all were obtained within 8
days of BuAg (a single outlier was within 25 days).
In addition, the records of 100 randomly selected
subjects from the laboratory list were further examined
for details of the clinical features and related workup of the illness that led to the ordering of BuAg and
the ultimate diagnosis of that illness. All 100 of these
selected cases were drawn from 2015, a year that
included a large mid-year outbreak of blastomycosis
associated with the Little Wolf River in Waupaca
County, Wisconsin.17 This allowed inclusion of
outbreak and nonoutbreak-related subjects tested with
BuAg (but, of course, only those seen and tested in our
health system).
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Inpatient and outpatient records from the index illness
were reviewed and included admission history;
physical examination, clinic, emergency department, or
urgent care notes from the time of initial presentation;
discharge summaries; notes from key consultants
(eg, infectious disease, pulmonary or critical care
medicine); key follow-up visit notes; and laboratory
and radiologic reports. Clinical features were recorded
if the EMR included documentation of either the
presence or absence of the sign or symptom.
Statistical Analysis
Categorical data were analyzed using Fisher’s exact
test. Normality testing utilized the Anderson-Darling
method. Continuous variables were compared with twosample t-tests of means for distributions approximating
normal (age), and Mann-Whitney test for non-normal
distributions (BuAg quantitative values). P-values less
than 0.05 were considered significant.

RESULTS

BuAg was performed on 836 individuals, who
represented 213 zip codes; mean age of population was
54.9 ± 18.0 (range: 5–95) years, 55.0% were male, and
78.9% were white. The last 7 months of 2013 yielded
94 BuAg tests (13.4/month), 261 tests were from 2014
(21.8/month), 356 from 2015 (outbreak year, 29.7/
month), and 125 were from the first 5 months of 2016
(25.0/month).
BuAg was positive in 49 of 836 (5.9%, representing 42
zip codes). Among positive tests, 16 of 49 (32.7%) were
part of the large 2015 outbreak. Among individuals
who were tested and had recorded exposure to the
outbreak geography (n=49), 16 (32.7%, representing
28 zip codes), were positive. BuAg-positive patients
were younger than those testing negative (Table 1),
even when outbreak subjects were removed (48.1
± 17.9 vs 56.7 ± 17.1 years, P=0.008); males were
overrepresented in testing positive. Those of Asian
ancestry, both those of Southeast Asia (P<0.0001) and
other parts of Asia (P=0.005), were overrepresented
compared to whites.
The sensitivity of BuAg was 87.9%, specificity 97.9%,
and positive predictive value 76.3% (based on 33
culture-positive cases). There were 2 additional cases
of blastomycosis diagnosed by positive histopathology
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or cytology/smear, 1 of which was BuAg-positive
(sensitivity for all 35 cases: 85.7%).
BuAg-Positive Population
Among the 49 BuAg-positive patients, 43 had
pulmonary disease (including 4 who additionally
had skin disease, 1 each who additionally had bone,
prostate, or central nervous system disease, and 2 with
widely disseminated involvement); 3 had skin-only
disease, and 3 had bone-only disease. The average
quantitative titer of all 49 patients was 2.7 ± 3.5 ng/ml;
the median titer was 1.4 (range: <0.2 to >14.7). Median
titer did not differ between outbreak and nonoutbreak
cases (1.2 vs 1.5, P=0.23), nor between cases with
and without apparent pulmonary disease (1.5 vs 1.2,
P=0.85) or pulmonary disease only versus disease
spread beyond the lungs (1.5 vs 1.3, P=0.50).
In the 15 cases (30.6% of the total 49) in which BuAg
was the only positive test for Blastomyces (in 3 cases
it was the only test performed), only 2 of 15 (13.3%)
subjects had blastomycosis identified beyond the lungs.
In cases where culture and/or histopathology and/or
cytology/smear also were positive, 13 of 34 (38.2%)
had disease beyond the lungs (P=0.10).
Only 2 of 19 (10.5%) culture-positive cases were
positive by Blastomyces antibody ID test, 0 of 17 by
antibody CF. Of those with positive BuAg, 16.1% of
those co-tested were positive by ID, 4.0% by CF. All
11 positive ID/CF cases were positive by BuAg. In the
Little Wolf River outbreak population, BuAg was the
only test performed for Blastomyces detection in 19 of
49 (38.8%) cases. Similar to nonoutbreak cases (31 of
34 [91.2%]), 14 of 16 (87.5%) BuAg-positive cases
had at least one other test for Blastomyces performed.
BuAg was the only positive test in 9 of 16 (56.3%)
outbreak cases versus 6 of 34 (17.6%, P=0.009)
nonoutbreak cases (8 of 14 vs 3 of 31, P=0.001, if only
co-tested cases are considered).
Serial BuAg tests were performed in 17 of 49 (34.7%)
positive index tests. A total of two tests were done in
11 cases, three tests in 4 cases, four tests in 1 case and
five tests in 1 case. The median time of first repeat test
was 45 days (range: 2–300 days), and 7 of 17 (41.2%)
second tests were negative (range: 30–300 days later).
All serial titers were lower than previous tests except
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Table 1. Demographic Features of BuAg-Tested Subjects
Total,
N=836

Positive BuAg,
n=49

Negative BuAg,
n=787

Female

376 (45.0%)

15 (4.0%)

361 (96.0%)

Male

460 (55.0%)

34 (7.4%)

426 (92.6%)

White

656 (78.5%)

26 (4.0%)

630 (96.0%)

Black

71 (8.5%)

5 (7.0%)

66 (93.0%)

0.215*

Hispanic

54 (6.5%)

3 (5.6%)

51 (94.4%)

0.478*

Asian

32 (3.8%)

12 (37.5%)

20 (62.5%)

0.0001*

8 (1.0%)

1 (12.5%)

7 (87.5%)

0.284*

Characteristic

†

Native American
Unknown
All nonwhite
Mean age ± SD
Mean age (adjusted ) ± SD
‡

P
0.039

10 (1.2%)

2 (20.0%)

8 (80.0%)

0.062*

175 (20.9%)

23 (13.1%)

152 (86.9%)

0.0001*

54.9 ± 18.0

40.3 ± 19.1

55.8 ± 17.5

0.0001

56.4 ± 17.2

48.1 ± 17.9

56.7 ± 17.1

0.008

*Compared to white race.
†

Includes 9 of 23 Southeast Asians (P<0.0001, compared to whites) and 3 of 9 other Asians (P=0.005).

‡

Outbreak-related subjects (n=49) removed.

BuAg, Blastomyces urine antigen; SD, standard deviation.

for 3 cases (maximum increase of 0.56 ng/ml over
index test value). Final serial titers were all lower than
the initial test or were negative. A second BuAg was
performed in 21 of 787 (2.7%) negative tests; median
time of repeat was 14 days (range: 1–510 days). One
test was repeated twice; all repeat tests were negative.
Histoplasma urine antigen was co-performed with
BuAg in 69.1% of all cases, and was positive in 25 of
578 (4.3%); 16 of these 25 (64.0%) were also BuAgpositive.
Patient Presentation
Of 100 patients who had BuAg testing and were
examined for index illness details, 87 presented with
pulmonary disease (including 1 patient each with
skin or bone involvement). The 13 nonpulmonary
presentations included skin (n=5), bone (n=2), central
nervous system (n=2), sinusitis (n=1), sepsis (n=1),
fatigue/weight loss (n=1), and pretransplant screening
(n=1). Seven patients were ultimately diagnosed with
blastomycosis (6 of which had positive BuAg); 7 had
other systemic fungal disease, 26 had noninfectious
lung disease, 22 had pneumonia, 5 had skin lesions,
6 had malignancies, 3 had mycobacteria, 11 had other
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specific diagnoses, and 1 had unknown etiology. Twelve
individuals were tested based on symptoms and/or
exposure, without definitive diagnosis, including 9
with cough/viral symptoms (5 of which had outbreak
exposure), 2 with fever of unknown source, and 1
exhibiting fatigue and weight loss. None of these 12
patients were BuAg-positive.
In the randomly selected cohort, 59 patients were
hospitalized during the illness. Time intervals from
onset of the index illness to the BuAg test and from
BuAg to final diagnosis are presented in Table 2.
Among the 100 patients tested with BuAg who
were examined in detail, 48 patients had at least one
fungal culture during the index illness and 19 had
histopathologic examination or cytology. Specific
testing for Histoplasma was performed on 65
patients, and 24 were tested for Coccidioides, 18 for
Cryptococcus, 30 for Aspergillus, 50 for mycobacteria
and 15 for Pneumocystis jirovecii.
Among those with active pulmonary symptoms at the
time of presentation (n=70) and whose records included
information regarding a particular symptom, a majority
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Table 2. Time, by Category, From Illness Onset to
Test and From Test to Diagnosis

From onset
to BuAg test

From BuAg
to diagnosis

<7 days, n

24

76

7–30 days, n

33

13

1–3 months, n

19

6

>3 months, n

8

2

Total N

84

97

Time category

BuAg, Blastomyces urine antigen.

had the following: dyspnea (44 of 50 [88%]), cough
(58 of 67 [87%]), fatigue (32 of 40 [80%]), myalgias/
muscle pain (12 of 20 [60%]), night sweats (14 of 24
[58%]), and fever (34 of 61 [56%]). A minority had
weight loss (42%), chest discomfort (30%), bone/joint
pain (24%), and hemoptysis (20%).

DISCUSSION

BuAg appears to be commonly utilized in this
large integrated health system with clinic locations
spanning eastern Wisconsin. The ultimate diagnoses
(pneumonia, noninfectious pulmonary processes, other
systemic fungal disease, malignancies, mycobacterial
disease) of the 100 randomly selected BuAg-tested
patients for detailed analysis are consistent with the
differential diagnosis of blastomycosis as presented in
texts and reviews,1,6 and with the results of a survey
of Wisconsin clinicians who were asked to list their
top three diagnoses when presented blindly with
various case vignettes of blastomycosis presentations.7
Similarly, for active pulmonary disease (while readily
acknowledging the limitations of retrospective EMR
review), mean age, gender distribution, and presenting
symptomatology was quite similar to that recently
reported from northern Wisconsin, except that dyspnea
was significantly more prevalent in the present
report.18 Thus, BuAg appears to be ordered in clinical
settings that indeed would include blastomycosis in the
differential diagnosis.
The calculated sensitivity of BuAg in this study,
85.7%, may be compared with the reports of Durkin et
al (92.9%, calculated from 42 cases),11 Connolly et al,
who used quantitative BuAg (89.9%, 89 cases),12 and
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Bariola et al, who used quantitative BuAg in newly
diagnosed patients (85.1%, 27 cases).15 It is apparently
similar to Azar et al (exact figure not reported).13
Our figure is higher than that reported by Frost and
Novicki (76.3%, 59 cases, mixture of qualitative and
quantitative BuAg), despite our study’s similarly
broad representation of patients from an endemic
area of Wisconsin.14 Our study exclusively included
quantitative BuAg, and the proportion of isolated
pulmonary cases was greater in their study (88%)
than ours (69%); however, such cases had the highest
BuAg sensitivity (82.7%) in their study.14
Ignoring cross-reactivity with Histoplasma, our
calculated specificity (97.9%) was similar to that of
Connolly et al (99.0%).12 Our cross-reactivity (64%)
was lower than that found by others (up to 96%),11,12,15
but still substantial. As previously suggested, further
tests and relative values of the two positive assays
can be considered to differentiate histoplasmosis from
blastomycosis.12,15 Fortunately, initial treatment of
these two mycoses is similar such that therapy may be
started while awaiting specific confirmation.1,2,19
The poor sensitivity of antibody testing by the older
CF and ID techniques is well known1-3 and was further
confirmed by our study. In no instance did these tests
contribute to the diagnosis of blastomycosis. The
current charge for each of these tests is approximately
$80, which may be saved by not ordering them.
Antibody testing for Blastomyces surface protein
BAD-1 by enzyme immunoassay, in combination
with BuAg, shows promise for sensitive and specific
blastomycosis diagnosis, as the former has minimal
cross-reactivity with Histoplasma.20
Based on recorded histories, 49 of 836 BuAgtested subjects had exposure to the environs of the
Little Wolf River during and shortly after the 2015
Waupaca County blastomycosis outbreak,17 with onethird testing positive for Blastomyces. BuAg testing
appeared particularly useful in this setting. As of this
writing, no summary of the complete outbreak has
been published.
Our study revealed that Asians were significantly
overrepresented regarding the proportion of those
tested with BuAg who were positive (37.5%). Recent
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studies have suggested differing susceptibility to
blastomycosis among different human genetic and
ethnic groups.12,21 Roy et al found significantly higher
blastomycosis incidence rates among Asians in
sporadic and outbreak cases.22 The genesis of these
findings is not clear, but the overrepresentation of
Asians in outbreak or hyperendemic areas may be
due to genetic predisposition and/or socioeconomic
reasons.
Finally, BuAg was the only positive test in a
significant portion of apparent blastomycosis cases.
Such cases may not be reported, as they do not meet
the Wisconsin case definition for blastomycosis.23
Thus, the true incidence of blastomycosis may be
underestimated.
Limitations
The limitations of our study include all of those
inherent in retrospective EMR reviews. Our
study was limited to a single health system in a
moderately high endemic area.24 The calculations of
test characteristics were based on 33 patients (not
unlike other studies).11,15 We were unable to provide
a comparison group of patients presenting with a
similar clinical presentation who were not tested with
BuAg. Our strengths included a moderately large,
comprehensive study of outpatients and inpatients
tested with BuAg (rather than just those who tested
positive or who were diagnosed with blastomycosis
by some means).

CONCLUSIONS

Blastomyces urine antigen testing appears to be
commonly performed in this region for work-up of
broad differential diagnoses that appropriately include
blastomycosis or for symptomatic patients with
known exposure to the fungus. It may be particularly
useful in outbreak settings. Fungal culture and BuAg
testing (perhaps with the future addition of antibody
testing for Blastomyces surface protein BAD-1) are
the preferred tests for Blastomyces in symptomatic
patients from an endemic area. Not adding highly
insensitive CF and ID tests to BuAg testing for
blastomycosis would save money without losing
sensitivity.
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Patient-Friendly Recap
• There are a number of diagnostic tests used
to confirm suspected blastomycosis, a fungal
infection of the lungs.
• One such test, referred to as BuAg, uses the
patient’s urine to look for byproducts of the
fungus Blastomyces.
• The author found that BuAg is commonly
ordered by local physicians and yields test
results reasonably comparable to the more
time-consuming culture method.
• Also shown was that a pair of alternative
antibody tests did not add true diagnostic
value, making their use inadvisable.
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